{"id":"placebo-gefitinib-tablets","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Diarrhea"},{"rate":"30-50%","effect":"Rash"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Anorexia"},{"rate":"5-20%","effect":"Dyspnea"},{"rate":"5-20%","effect":"Cough"},{"rate":"5-10%","effect":"Pneumonia"},{"rate":"1-5%","effect":"Acute respiratory distress syndrome"}]},"_chembl":{"chemblId":"CHEMBL939","moleculeType":"Small molecule","molecularWeight":"446.91"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by selectively inhibiting the tyrosine kinase activity of the EGFR, thereby blocking the signal transduction pathways that lead to cell proliferation and survival. This results in the inhibition of tumor growth and metastasis.","oneSentence":"Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:37.989Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Locally advanced or metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04248829","phase":"PHASE3","title":"Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2020-02-13","conditions":"Non-Small Cell Lung Cancer","enrollment":393},{"nctId":"NCT03866499","phase":"PHASE3","title":"A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beta Pharma Shanghai","startDate":"2021-04-30","conditions":"NSCLC","enrollment":369},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT04239833","phase":"PHASE3","title":"A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2020-01-31","conditions":"Non-Small Cell Lung Cancer","enrollment":240},{"nctId":"NCT02416739","phase":"PHASE2, PHASE3","title":"Anticancer Activity of Nicotinamide on Lung Cancer","status":"UNKNOWN","sponsor":"Il Yeong Park, Ph.D.","startDate":"2015-03","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":110},{"nctId":"NCT02889692","phase":"PHASE3","title":"Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2013-03","conditions":"Cancer","enrollment":23},{"nctId":"NCT03856697","phase":"PHASE3","title":"Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation","status":"UNKNOWN","sponsor":"Hangzhou ACEA Pharmaceutical Research Co., Ltd.","startDate":"2019-03","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":406},{"nctId":"NCT00656136","phase":"PHASE3","title":"BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":585},{"nctId":"NCT01745302","phase":"","title":"Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma","status":"UNKNOWN","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2011-11","conditions":"Cancer","enrollment":470},{"nctId":"NCT00259064","phase":"PHASE2, PHASE3","title":"Iressa v BSC (Best Supportive Care) in First Line NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"NSCLC","enrollment":216},{"nctId":"NCT00770588","phase":"PHASE4","title":"Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-09","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":296},{"nctId":"NCT00088907","phase":"PHASE3","title":"Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-08","conditions":"Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer","enrollment":270},{"nctId":"NCT00077025","phase":"PHASE2","title":"Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-01","conditions":"Breast Cancer","enrollment":174},{"nctId":"NCT01502202","phase":"PHASE2","title":"Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2012-03","conditions":"Non Small Cell Lung Cancer, Adenocarcinoma","enrollment":162},{"nctId":"NCT00080743","phase":"PHASE2","title":"Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2004-01","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT00229723","phase":"PHASE2","title":"IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Neoplasms, Squamous Cell","enrollment":224},{"nctId":"NCT00242801","phase":"PHASE3","title":"Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-07","conditions":"NSCLC","enrollment":1692}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo Gefitinib Tablets","genericName":"Placebo Gefitinib Tablets","companyName":"Hangzhou ACEA Pharmaceutical Research Co., Ltd.","companyId":"hangzhou-acea-pharmaceutical-research-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Used for Non-small cell lung cancer, Locally advanced or metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}